Article Text

other Versions

Download PDFPDF
Selective retina therapy for acute central serous chorioretinopathy
  1. C Klatt1,
  2. M Saeger1,
  3. T Oppermann1,
  4. E Pörksen1,
  5. F Treumer1,
  6. J Hillenkamp1,
  7. E Fritzer2,
  8. R Brinkmann3,
  9. R Birngruber3,
  10. J Roider1
  1. 1Department of Ophthalmology, University Medical Center Schleswig-Holstein, Kiel, Germany
  2. 2Institute for Medical Informatics and Statistics, Christian-Albrechts University of Kiel, Kiel, Germany
  3. 3Medical Laser Center Lübeck, Lübeck, Germany
  1. Correspondence to Dr Carsten Klatt, Department of Ophthalmology, University Medical Center Schleswig-Holstein, Arnold-Heller Strasse 3, Haus 25, Kiel D-24105, Germany; cklatt{at}


Aims To evaluate selective retina therapy (SRT) as a treatment of acute central serous chorioretinopathy.

Methods 30 eyes of 30 patients with central serous chorioretinopathy of at least a 3 months' duration were recruited. 14 eyes were randomised to an SRT group (Q-switched neodymium-doped yttrium lithium fluoride (Nd:YLF) laser, wavelength 527 nm, t=1.7 μs, energy 100–370 μJ, spot diameter 200 μm, pulse repetition rate 100 Hz,) and 16 eyes to a control group. After 3 months of follow-up, patients in the control group with persistence of subretinal fluid (SRF) were allocated to a cross-over group, treated with SRT and followed up for further 3 months. The main outcome measures were change of best-corrected Early Treatment Diabetic Retinopathy Study visual acuity (BCVA) and SRF.

Results At 3 months of follow-up, the mean (SD) improvement of BCVA was significantly greater after SRT than in the control group: 12.7 (7.2) versus 6.3 (8.9) letters (p=0.04). SRF had decreased significantly more after SRT as compared with that the control group: 203 (136) μm versus 41 (150) μm (p=0.005). In eight eyes allocated to the cross-over group, the mean BCVA had increased during 3 months of follow up before SRT by 1.4 (5.2) letters and continued to increase during 3 months following SRT by 7.4 (6.3) letters, while SRF increased by 39.5 (160.2) μm before SRT and decreased by 151.5 (204.9) μm after SRT. In six of the eight eyes, SRF had completely resolved 3 months after SRT.

Conclusions SRT appears to expedite functional recovery and the re-absorption of SRF as compared with that in untreated controls. A larger prospective, randomised phase 3 confirmative patient study is warranted.

Trial registration number: NCT00987077

  • Central serous chorioretinopathy
  • selective retina therapy
  • laser
  • retina
  • macula
  • treatment lasers

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests Declared. Johann Roider, Ralf Brinkmann and Reginald Birngruber hold patents on selective retina therapy. Carsten Klatt, Mark Saeger, Till Oppermann, Erk Pörksen, Felix Treumer, Jost Hillenkamp and Elfriede Fritzer have no competing interests.

  • Ethics approval This study was conducted with the approval of the University Medical Center of the Christian-Albrechts-University, Kiel.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh